Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement.
BACKGROUND
Although guidelines now recommend polytherapy to achieve blood pressure targets, little is know about which antihypertensive drugs are combined in clinical practice.


OBJECTIVE
To examine current practices for the coprescribing of antihypertensive agents.


METHODS
A population-based cohort study was performed using linked administrative databases on all Ontario residents 66 years of age or older who were newly treated for hypertension between July 1, 1994, and March 31, 2002, and did not have diabetes or other relevant comorbidities. All patients were followed for two years to determine which antihypertensives were prescribed concurrently.


RESULTS
Of the 166,018 patients in the described cohort, 1819 (1%) were prescribed a combination therapy tablet as their first-line therapy. The number of patients prescribed antihypertensive polytherapy within the first two years of diagnosis increased from 2071 (21%) of the 9825 hypertensive patients starting treatment in the second half of 1994 to 2578 (37%) of the 6988 hypertensive patients beginning treatment in the first quarter of 2002 (P<0.0001). Overall, 11,003 (27%) of polytherapy prescriptions were for drugs without additive hypotensive effects when combined and this proportion did not change over time.


CONCLUSIONS
Although there has been an increase in the use of polytherapy in elderly hypertensive patients without comorbidities in Ontario over the past decade, more than one-quarter of the two drugs prescribed together have not been proven to have additive hypotensive effects. Because this likely contributes to suboptimal blood pressure control rates, future guidelines and educational programs should devote increased attention to the choice of optimal polytherapy combinations.
Campbell
Norman R C
NR
Department of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.
McAlister
Finlay A
FA
Duong-Hua
Minh
M
Tu
Karen
K
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D019992:Databases as Topic; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017723:Drug Utilization Review; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009864:Ontario; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011446:Prospective Studies
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics
JAMA. 2003 May 14;289(18):2363-9
12746359
Lancet. 2005 Sep 10-16;366(9489):907-13
16154017
J Am Coll Cardiol. 2004 Aug 4;44(3):E1-E211
15358047
Cardiovasc Drugs Ther. 1988 Mar;1(6):657-60
3154330
Drugs. 1995 Sep;50(3):560-86
8521773
Lancet. 2002 Mar 23;359(9311):1004-10
11937179
CMAJ. 2006 Jun 6;174(12):1737-42
16754904
J Hypertens. 2003 Jun;21(6):1055-76
12777939
Am J Hypertens. 1996 Dec;9(12 Pt 2):187S-191S
8968432
J Hypertens. 2004 Feb;22(2):425-30
15076203
J Hum Hypertens. 1997 Apr;11(4):249-50
9185031
Lancet. 1999 Jun 12;353(9169):2008-13
10376615
J Hypertens. 2002 Jul;20(7):1255-7
12131513
Lancet. 2004 Jun 19;363(9426):2022-31
15207952
J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):1083-5
6196558
Am J Hypertens. 2001 Sep;14(9 Pt 1):963-8
11587165
Eur Heart J. 2005 Feb;26(4):384-416
15681577
BMJ. 2003 Jun 28;326(7404):1419
12829553
Am J Hypertens. 2003 Nov;16(11 Pt 2):36S-40S
14625159
J Hypertens Suppl. 1990 Sep;8(4):S83-6
2258790
Can Fam Physician. 2002 Oct;48:1662-5
12449551
J Hypertens. 2003 Jun;21(6):1011-53
12777938
J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404
12461301
J Hypertens. 1996 Aug;14(8):1041-5
8884561
J Hum Hypertens. 1998 Nov;12(11):761-3
9844947
Eur J Clin Pharmacol. 1988;34(3):249-53
3294021
Am J Hypertens. 1989 Mar;2(3 Pt 1):154-7
2522008
BMJ. 1992 Feb 15;304(6824):405-12
1445513
CMAJ. 1997 May 1;156(9):1273-87
9145054
J Hypertens Suppl. 1989 Dec;7(6):S250-1
2698934
Circulation. 2006 Jan 17;113(2):213-21
16391156
J Hypertens. 2005 Apr;23(4):883-9
15775795
J Clin Pharmacol. 1987 Jan;27(1):41-5
3316303
BMJ. 2003 Jun 28;326(7404):1427
12829555
Lancet. 1998 Jun 13;351(9118):1755-62
9635947
J Clin Hypertens (Greenwich). 2003 Sep-Oct;5(5):330-5
14564133
Arch Intern Med. 2005 Jun 27;165(12):1410-9
15983291
Curr Hypertens Rep. 2001 Jun;3(3):203-8
11353570
J Hum Hypertens. 1995 Oct;9(10):791-6
8576893
Drugs. 1988 Oct;36(4):387-428
3069435
J Hum Hypertens. 1990 Apr;4(2):157-9
2338688
Hypertension. 2005 Jun;45(6):1113-8
15851629
BMJ. 1998 Sep 12;317(7160):703-13
9732337
Hypertension. 2005 May;45(5):880-6
15809363
JAMA. 2003 May 21;289(19):2534-44
12759325
JAMA. 2003 May 21;289(19):2560-72
12748199
J Hum Hypertens. 2004 Mar;18(3):139-85
14973512
Circulation. 2005 Sep 20;112(12):e154-235
16160202
Can J Cardiol. 2005 Jun;21(8):657-72
16003449
Lancet. 2005 Oct 29-Nov 4;366(9496):1545-53
16257341
Hypertension. 2006 Jan;47(1):22-8
16344380
Clin Exp Hypertens A. 1988;10(5):791-800
3180489